Indivior PLC’s (INDV) “Buy” Rating Reaffirmed at Numis Securities Ltd
Numis Securities Ltd reissued their buy rating on shares of Indivior PLC (LON:INDV) in a research note released on Thursday. The firm currently has a GBX 490 ($6.38) price objective on the specialty pharmaceutical company’s stock.
INDV has been the topic of several other research reports. Jefferies Group LLC reissued a buy rating and issued a GBX 490 ($6.38) price objective on shares of Indivior PLC in a research report on Thursday, May 4th. Stifel Nicolaus reissued a buy rating and issued a GBX 500 ($6.51) price objective on shares of Indivior PLC in a research report on Thursday, May 4th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of GBX 430.71 ($5.61).
Shares of Indivior PLC (LON:INDV) opened at 375.60 on Thursday. The company has a 50-day moving average price of GBX 319.90 and a 200-day moving average price of GBX 325.61. Indivior PLC has a 1-year low of GBX 261.30 and a 1-year high of GBX 392.00. The company’s market cap is GBX 2.71 billion.
TRADEMARK VIOLATION WARNING: “Indivior PLC’s (INDV) “Buy” Rating Reaffirmed at Numis Securities Ltd” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.watchlistnews.com/indivior-plcs-indv-buy-rating-reaffirmed-at-numis-securities-ltd/1463202.html.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.